Bristol Myers Squibb Files 8-K on Financials

TL;DR

BMS filed an 8-K on Feb 6, 2025, covering financial results and operations.

AI Summary

Bristol Myers Squibb Company filed an 8-K on February 6, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. Specific details regarding financial performance or significant events are not elaborated in the provided text excerpt.

Why It Matters

This filing provides an update on Bristol Myers Squibb's financial condition and operations, which is crucial for investors to assess the company's performance and make informed decisions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial information and does not appear to contain any immediate negative news or significant risk factors.

Key Players & Entities

• Bristol Myers Squibb Company (company) — Registrant
• February 6, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 Par Value BMY New York Stock Exchange

Filing Documents

• bmy-20250206.htm (8-K) — 35KB
• a2024ex991-filing.htm (EX-99.1) — 1064KB
• q42024earningspresentati.htm (EX-99.2) — 26KB
• bmslogoa.jpg (GRAPHIC) — 11KB
• q42024earningspresentati001.jpg (GRAPHIC) — 34KB
• q42024earningspresentati002.jpg (GRAPHIC) — 266KB
• q42024earningspresentati003.jpg (GRAPHIC) — 46KB
• q42024earningspresentati004.jpg (GRAPHIC) — 68KB
• q42024earningspresentati005.jpg (GRAPHIC) — 97KB
• q42024earningspresentati006.jpg (GRAPHIC) — 106KB
• q42024earningspresentati007.jpg (GRAPHIC) — 113KB
• q42024earningspresentati008.jpg (GRAPHIC) — 71KB
• q42024earningspresentati009.jpg (GRAPHIC) — 98KB
• q42024earningspresentati010.jpg (GRAPHIC) — 44KB
• q42024earningspresentati011.jpg (GRAPHIC) — 106KB
• q42024earningspresentati012.jpg (GRAPHIC) — 107KB
• q42024earningspresentati013.jpg (GRAPHIC) — 120KB
• q42024earningspresentati014.jpg (GRAPHIC) — 109KB
• q42024earningspresentati015.jpg (GRAPHIC) — 98KB
• q42024earningspresentati016.jpg (GRAPHIC) — 87KB
• q42024earningspresentati017.jpg (GRAPHIC) — 101KB
• q42024earningspresentati018.jpg (GRAPHIC) — 96KB
• q42024earningspresentati019.jpg (GRAPHIC) — 92KB
• q42024earningspresentati020.jpg (GRAPHIC) — 95KB
• q42024earningspresentati021.jpg (GRAPHIC) — 57KB
• 0000014272-25-000037.txt ( ) — 4176KB
• bmy-20250206.xsd (EX-101.SCH) — 4KB
• bmy-20250206_def.xml (EX-101.DEF) — 15KB
• bmy-20250206_lab.xml (EX-101.LAB) — 33KB
• bmy-20250206_pre.xml (EX-101.PRE) — 24KB
• bmy-20250206_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 6, 2025, Bristol-Myers Squibb Company (the "Company") issued a press release (the "Earnings Press Release") announcing its financial results for the fourth quarter of 2024 and full year of 2024. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 6, 2025, the Company posted on its website at www.bms.com a presentation (the "Bristol Myers Presentation") on certain financial and operating initiatives available for viewing during the Company's conference call and webcast announcing its financial results for the fourth quarter of 2024 and full year of 2024 at 8:00 a.m. Eastern time. A copy of the Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. The Earnings Press Release and the Bristol Myers Presentation include references to non-GAAP financial information. Reconciliations between the non-GAAP financial measures and the comparable GAAP financial measures and the reasons for the presentation of such non-GAAP financial measures, are available in the Earnings Press Release which is included as Exhibit 99.1 hereto. The Bristol Myers Presentation should be read in conjunction with the Earnings Press Release. The Company reserves the right to discontinue availability of the Bristol Myers Presentation from its website at any time. Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by the Company under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished as part of this Current Report on Form 8-K: Exhibit No. Description 99.1 Press release of Bristol-Myers Squibb Company dated February 6, 2025 99.2 Presentation Materials of Bristol-Myers Squibb Company dated February 6, 2025 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRISTOL-MYERS SQUIBB COMPANY Dated: February 6, 2025 By: /s/ Amy Fallone Name: Amy Fallone Title: Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR